In consultation: Guidance and quality standards
Showing 1 to 7 of 7
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843] | Draft guidance | Technology appraisal guidance | |
| Lifileucel for previously treated unresectable or metastatic melanoma ID3863 | Draft guidance | Technology appraisal guidance | |
| Filgotinib for treating axial spondyloarthritis ID6594 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325] | Final draft guidance | Technology appraisal guidance | |
| Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over ID6542 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Guidance on the use of electroconvulsive therapy | Review proposal consultation | Technology appraisal guidance | |
| Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance |